Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Latest articles

Four Decades of IPOs: An Overview

An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.

24 Apr 2024

Larry Page: The Mastermind Behind Google

Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.

24 Apr 2024

Mark Leonard: The Mysterious Brain Behind Constellation Software

Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.

24 Apr 2024

Ticker symbol

Country

🇺🇸 United States